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Outpatient Management of Cholesteatoma with Canal Wall
Reconstruction Tympanomastoidectomy
Richard Kao, MD; Todd Wannemuehler, MD; Charles W. Yates, MD; Rick F. Nelson, MD, PhD
Objectives: The postoperative wound infection rate for canal wall reconstruction (CWR) tympanomastoidectomy with
mastoid obliteration in the treatment of chronic otitis media with cholesteatoma has been reported to be 3.6%. Postoperative
administration of 24–48 hours of intravenous antibiotics has been recommended. We aim to determine the infection rate of
CWR with postoperative outpatient oral antibiotics.
Study Design: Institutional review board—approved retrospective case review.
Setting: Tertiary referral center.
Patients: Retrospective review of consecutive patients who underwent CWR tympanomastoidectomy with mastoid oblitera-
tion at a single institution from 2014 to 2016.
Main Outcome Measure: Patient characteristics (age, sex) were calculated. Rate of postoperative complications and infec-
tions within 1 month of surgery were calculated. Comparison to previous published infection rates with postoperative intra-
venous antibiotics.
Results: 51 patients underwent CWR followed by outpatient oral antibiotics with a mean age of 25.9 years (16 patients
were less than 10 years old). There were no postoperative wound infections. Outpatient antibiotics showed non-inferiority to
IV antibiotic historic controls (0% vs. 3.6%; 95% confidence interval [CI], 0–6.09%; p50.03). One patient had small postop-
erative wound dehiscence with CSF leak that was managed conservatively. One patient developed Clostridium difficile colitis
on postoperative day 2.
Conclusions: The infection rate after CWR tympanomastoidectomy with use of outpatient antibiotics is low and is non-
inferior to a historic cohort treated with inpatient intravenous antibiotics. A larger randomized controlled trial is warranted.
Key Words: Canal wall reconstruction, cholesteatoma, antibiotics, outpatient, tympanomastoidectomy.
Level of Evidence: 4.
INTRODUCTION
Canal wall reconstruction tympanomastoidectomy
with mastoid obliteration (CWR) for the treatment of
chronic otitis media with cholesteatoma is a technique
that has a low recurrence rate and preserves the ear
canal anatomy.1,2 The primary goals of any surgical
treatment of cholesteatoma are to eradicate the choles-
teatoma and create a dry ear with a low chance of cho-
lesteatoma recurrence. The secondary goals include
maximizing hearing and limiting lifetime mastoid cavity
cleanings and water restrictions.
Traditionally, canal wall up (CWU) and canal wall
down (CWD) have been the most common procedures
used to treat cholesteatoma. CWU has the advantage of
preserving normal ear canal anatomy and middle ear
space. The disadvantage of CWU is the high rate of
recurrent cholesteatoma ranging from 40–60% in chil-
dren and 20% in adults.3–8 The major advantage of
CWD is the increased exposure and the relatively low
rate of cholesteatoma recurrence of 7–17%.9–11 The
major disadvantage is the need for lifelong mastoid bowl
cleanings, risk of mastoid bowl infections, limitations on
water activities and typically worse conductive hearing
results. In contrast, CWR combines the advantages of
both CWU and CWD without the need for mastoid bowl
cleanings and, most importantly, a low rate of recurrent
disease (2.6% requiring conversion to CWD or subtotal
petrosectomy and 12% residual disease at second
look).2
The CWR procedure involves harvesting bone p&ate
that is used to obliterate the mastoid cavity during canal
reconstruction (Fig. 1A). Early in the development of the
CWR technique, the rate of postoperative wound infec-
tion of the mastoid was as high as 14.4%.1 Possible
causes for the high postoperative infection rate included:
1) bacterial contamination of the bone p&ate from the
mastoid air cells during harvesting, 2) inadequate post-
operative antibacterial treatment, or 3) non-viable or
acellular bone p&ate. Subsequently, the technique was
modified to harvest bone p&ate without contamination of
diseased mastoid air cells, wash the p&ate with bacitracin
solution, and administer 24–48 hours of postoperative
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intravenous (IV) antibiotics. Subsequently, the infection
rate decreased to 3.6%.1,2 Thus, it has been recom-
mended that patients be admitted after CWR for admin-
istration of IV antibiotics. However, the need for
postoperative admission can discourage surgeons from
performing CWR and potentially increase hospital costs.
Traditionally after CWR, patients have been treated
empirically to cover Pseudomonas aeruginosa with 24 to
48 hours of IV levofloxacin and piperacillin-tazobactam
(Zosyn, Pfizer Corporation, New York, New York) fol-
lowed by outpatient oral levofloxacin for 2 weeks.1
Patients younger than 18 years are treated with Zosyn
without levofloxacin. Penicillin-allergic patients were
typically treated with 24–48 hours of IV clindamycin
with or without levofloxacin, followed by outpatient oral
clindamycin for 2 weeks. Additionally, levofloxacin may
be substituted with ciprofloxacin depending on
availability.2
While it is recognized that a regimen of antibiotics
is recommended after CWR procedures for cholestea-
toma,1 there exists a paucity of literature investigating
the necessity of admission for IV antibiotic administra-
tion in postoperative management protocols. This study
seeks to determine the efficacy and safety of an outpa-
tient antibiotic regimen following CWR for cholestea-
toma to obviate the need for postoperative hospital
admission.
MATERIAL AND METHODS
Institutional review board (IRB) exemption through the
Indiana University Office of Research Compliance Human Sub-
jects Division was obtained for the planned retrospective review
prior to initiating patient identification or chart review (IRB
number 1608119193, Principle Investigator RFN). Electronic
medical records and operative notes were reviewed retrospec-
tively to obtain: 1) patient age, 2) gender, 3) surgical side, 4)
intraoperative antibiotic(s), 5) postoperative antibiotic(s), 6)
postoperative infections, and 7) postoperative complications.
Patients were treated with CWR if they had: 1) cholestea-
toma involving the antrum and/or mastoid, 2) an intact poste-
rior ear canal wall (either primary or after previous CWU at
another institution), and 3) limited dural exposure from choles-
teatoma disease. These criteria were the same inclusion criteria
as historical controls.1,2 There was no treatment bias made pre-
operatively based on severity of infection.
Inclusion criteria for the current study included: 1) having
received tympanomastoidectomy with CWR for cholesteatoma
and 2) having received only oral antibiotics after the operation.
Subjects were excluded if they received any postoperative IV
antibiotics. These subjects received IV antibiotics as they were
unable to tolerate oral medications due to nausea and/or
emesis.
Rate of infection was quantified, and statistical analysis
was performed. Non-inferiority binomial testing was conducted
using SAS v9.4 (SAS Institute, Cary, North Carolina). For all
analyses, p<0.05 was selected as the criterion for statistical
significance.
Surgical Technique
The post-auricular area is shaved, prepped with Chlorap-
rep (Becton, Dickinson and Company, Franklin Lakes, NJ) and
injected with 1% lidocaine with 1:100,000 epinephrine (weight-
adjusted for pediatric patients). The skin and hemi-face are
then prepped with betadine and the patient is draped. The
post-auricular incision is made at the hairline down to the tem-
poralis fascia. An anterior based periosteal (Palva) flap is ele-
vated. In revision cases, the flap is not elevated to prevent
exposure of mastoid contents. Bone p&ate is harvested in all
cases with a 6 mm 2-Flute otologic bur (Stryker Corporation,
Kalamazoo, Michigan) from the temporal or occipital cortex
using an inline suction collector (Sheehy Bone Dust Collector,
Grace Medical, Memphis, Tennessee). The bone p&ate is soaked
in 50,000 units of bacitracin during the case. No Penrose drain
was placed as had previously been described.1,2 The palva flap
and subcutaneous layers were closed with 3-0 Vicryl sutures
and the skin was closed with 4-0 subcuticular Moncryl sutures.
The incision was covered with Dermabond (Ethicon Inc., Somer-
set, New Jersey). Thus, the patient did not need to perform
postoperative wound care. The Dermabond was typically
removed at the 1-month visit. The remainder of the procedure
has been previously described.1
All patients receive intraoperative IV antibiotics prior to
skin incision. In most cases, the patients are administered IV
Zosyn or IV ciprofloxacin.
Postoperative Management
After the procedure, patients are treated with a 7- or 10-
day course of oral antibiotics as well as pain control. Adults are
most often prescribed a fluoroquinolone (ciprofloxacin) and chil-
dren are most often prescribed sulfamethoxazole-trimethoprim.
If the patient is allergic to these antibiotics, an alternative anti-
biotic is appropriately prescribed. Patients are then seen in
Fig. 1. Representative Canal Wall Recon-
struction. (A) The reconstructed ear canal
is seen with the two superior cuts and the
inferior compound miter cut (white arrows).
The mastoid is filled with bone p&ate (*). (B)
Representative transcanal view of recon-
structed ear canal after second look tym-
panoplasty with ossicular reconstruction
and cartilage graft (arrowhead).
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clinic 1 week after the operation for examination and ear canal
pack removal. Subsequently, patients are given otic drops (oflox-
acin or ciprofloxacin-dexamethasone) to use daily and then
examined again in 1 month after the operation. Postoperative
complications, if present, are noted at these visits.
RESULTS
A total of 55 patients underwent CWR from October
2014 to May 2017. All patients who presented with a
cholesteatoma that extended into the antrum or mastoid
and an intact posterior canal wall were treated with
CWR with mastoid obliteration with bone p&ate (Fig. 1A).
Most patients have undergone second look tympano-
plasty with ossicular reconstruction and cartilage graft
at 6 months after CWR (Fig. 1B).
In our series, two patients initially presented with
cholesteatoma and lateral semicircular canal dehiscence
and were included. Four patients were excluded from
the study because they received IV antibiotics postopera-
tively due to inability to tolerate oral medications in the
postoperative period. Therefore, 51 patients (n5 51) who
had undergone CWR tympanomastoidectomy including
mastoid obliteration were identified and included in this
analysis. The mean age was 25.96 21.4 years (standard
deviation, range 3–67).
Sixteen subjects were less than 10 years of age.
There were nearly equal distributions of operative sides
(25 right; 26 left) and gender (28 males; 23 females).
Nearly all subjects received anti-pseudomonal antibiotics
intraoperatively (Table I). The most common intraopera-
tive antibiotics were Zosyn (n5 36; 70.5%), ciprofloxacin
(n5 6, 11.7%), and ciprofloxacin with Zosyn (n5 1,
2.0%). Those with penicillin allergies received clindamy-
cin (n5 1, 2.0%) or clindamycin with ciprofloxacin (n5 2,
3.9%). Seven patients (13.7%) did not receive preopera-
tive anti-pseudomonal antibiotics, but received cefazolin
instead.
A vast majority of patients were discharged the
same day as their procedure on an outpatient basis
(n5 45, 88.2%, Table I). Of those requiring observation,
the most common reason was due to the operative case
ending after 5 p.m. and nausea and vomiting (five of six
patients). One patient required observation due to con-
genital aortic and pulmonary artery stenosis. Postopera-
tive oral antibiotics were given to all patients even the
patients that required observation overnight. The most
common antibiotic given was sulfamethoxazole/trimetho-
prim (n528; 54.9%) followed by ciprofloxacin or levoflox-
acin (n520, 39.2%). In most cases, adults were
prescribed fluoroquinolones, and pediatric patients were
prescribed weight-based sulfamethoxazole/trimethoprim
(8–10 mg/kg/day divided every 12 hours). The most com-
mon duration of oral antibiotics was 7 days.
There were no postoperative surgical site infections
in this series (Table I).
We compared our findings with a historic cohort
where the reported infection rate was 3.6% when
patients were given 24–48 hours of IV antibiotics in the
postoperative period.2 Outpatient antibiotics showed
noninferiority to IV antibiotic historic controls (0% vs.
3.6%; 95% CI, 0–6.09%; p5 0.03).
Notable non-infectious complications included one
patient who had small postoperative wound dehiscence
with CSF leak that was successfully managed conserva-
tively with additional skin sutures. Intraoperatively for
this patient, the superior canal wall cut resulted in a
dural tear that was managed with a temporalis muscle
plug and replacement of the canal bone. One patient,
taking sulfamethoxazole/trimethoprim, developed Clos-
tridium difficile colitis on postoperative day 2 which
resolved with oral ciprofloxacin and metronidazole. Two
pediatric patients developed postauricular dermatitis
likely related to 2-Octyl Cyanoacrylate, commonly
known as Dermabond. This resolved following removal
of the Dermabond and use of oral diphenhydramine.
DISCUSSION
CWR tympanomastoidectomy represents a unique
surgical technique to manage cholesteatoma.1 It provides
increased visualization of the middle ear, anterior epi-
tympanum, and sinus tympani during extirpation of cho-
lesteatoma. The rates of recurrent cholesteatoma are
significantly lower than found in CWU tympanomastoi-
dectomy, and it concurrently preserves the normal ear
canal anatomy.2 Thus, it has the potential to improve
healthcare costs and quality of life by avoiding lifetime
mastoid cavity cleanings and water restrictions.
The major modifications of CWR technique in the
past decade include harvesting bone p&ate without con-
tamination of diseased mastoid air cells, washing the
p&ate with bacitracin solution, and administering 24–48
hours of postoperative IV antibiotics. These methods
were utilized to address possible bacterial contamination
of the bone p&ate being replaced into the mastoid, and
the infection rate dropped to 4.5%1 and most recently to
a rate of 3.6%.2 In this 2014 study,2 it is important to
note that some patients received up to 48 hours of intra-
venous antibiotics and some patients received oral anti-
biotics based upon surgeon preference; therefore this
infection rate of 3.6% represents a mixed cohort. Yet,
postoperative admission for administration of IV antibi-
otics over the first 24–48 postoperative hours remains
the most common practice.2 Because of this, surgeons
may be discouraged from performing this procedure on
an outpatient basis.
The most common bacteria isolated from postopera-
tive CWR infections are P. aeruginosa methicillin-
resistant Staphylococcus aureus (MRSA), Enterobacter
cloacae, Staphylococcus epidermidis and mixed flora.1 P.
aeruginosa is a gram-negative rod with facultative
anaerobic metabolism and is commonly seen in the outer
ear.12 Antibiotics that are known to be effective against
P. aeruginosa include aminoglycosides (gentamicin), fluo-
roquinolones (ciprofloxacin, levofloxacin), cephalosporins
(cefepime, ceftazidime), certain penicillins (ticarcillin,
piperacillin), carbapenems (meropenem, imipenem), pol-
ymyxins (polymyxin B), and monobactams (aztreo-
nam).13 The only oral anti-pseudomonal antibiotics are
aminoglycosides (gentamicin) and fluoroquinolones (cip-
rofloxacin, levofloxacin). The toxicities of gentamicin,
including cochleovestibular toxicity resulting in hearing
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loss, vestibular dysfunction, and renal toxicity; make it
unfavorable for use in prophylaxis. Thus, oral ciprofloxa-
cin and levofloxacin, which have the same bioavailability
as IV formulations, have become popular choices in oral
antibiotic coverage of P. aeruginosa infections.14,15 Yet,
fluoroquinolones are not recommended in children due
to the risk of arthropathy and tendinopathy.16 Therefore,
there are limited options for anti-pseudomonal prophy-
laxis and treatments in children.
Community-acquired methicillin-resistant Staphylo-
coccus aureus (MRSA) is typically sensitive to sulfameth-
oxazole/trimethoprim and clindamycin.17 MRSA
resistance to clindamycin varies widely from 12 to 76 per-
cent across the United States,18 and thus clindamycin
may not be a reliable antibiotic in MRSA coverage. Sulfa-
methoxazole/trimethoprim is effective at treating not only
gram-positive bacteria (Staphylococcus aureus, Strepto-
coccus pneumonia), but also gram-negative bacteria (Hae-
mophilus influenzae, Klebsiella pneumonia). For these
reasons, it is effective in treating chronic otitis media19
and acute otitis media in the pediatric population.20
In this study, we administered IV anti-pseudomonal
antibiotics preoperatively in the majority of patients. In
children, we most commonly used a weight-based oral
sulfamethoxazole/trimethoprim regimen postoperatively.
While sulfamethoxazole/trimethoprim does not cover
Pseudomonas sp., it is an optimal oral antibiotic for
most community acquired MRSA. In adults, we most
commonly used oral ciprofloxacin, which has the same
bioavailability as the IV formulation.
Nearly all patients presenting to our facility with
cholesteatoma underwent CWR, unless there was very
limited attic disease or the posterior canal wall was
unable to be reconstructed as noted on preoperative
imaging. There was no bias for choosing CWR as a sur-
gical method based on severity of infection, nor was
there bias in choosing postoperative antibiotics. Any var-
iability in postoperative antibiotic regimen was due to
medication allergies and drug interactions. Most impor-
tantly, variability in antibiotics did not produce any dif-
ferences in postoperative infection rates.
This selection process is identical to those of our
historical controls.1,2 In fact, two of the patients in our
series had lateral semicircular canal fistulas due to
extensive cholesteatoma preoperatively. Of note, neither
of these patients experienced sensorineural hearing loss
and both had no residual disease at second look.
While our case series showed a postoperative infec-
tion rate of 0% with the use of only oral antibiotics in
the postoperative period, these data do not indicate that
outpatient antibiotics are better than IV antibiotics. Sim-
ply, our data demonstrate that the infection rate is very
low when CWR is performed with outpatient oral antibi-
otics. Surgeons may use their discretion to treat patients
with IV antibiotics in the postoperative period based
upon the extent of infection.
The causes of postoperative infection are certainly
multifactorial. Prior to employing the outpatient antibi-
otic regimen, it is important to consider the patient’s
home environment and whether they are capable of
adhering to aseptic wound care instructions. In our case
series, all subjects reported to have taken their oral anti-
biotics course. In our series, the wound is sutured with
absorbable sutures and covered with dermabond without
the use of a Penrose drain. Thus, patient-directed wound
care is not needed. All subjects returned for their 1-week
and 1-month follow-up appointments.
Another technical modification, in addition to those
discussed above, was the exclusive use of 2-Flute otologic
burs. Bone p&ate harvested with these burs results in
larger chip size, higher osteoblast cellular content and
thus high bone viability.21 This may facilitate decreased
postoperative infection rates and wound healing, but
future studies are needed.
Placing all CWR patients in observation (24 hours)
or inpatient (48 hours) status for IV antibiotics has the
potential to add additional cost to the hospital and
patient. In contrast, treatment of a CWR wound infec-
tion could be costly with multiple days of IV antibiotics.
Thus, outpatient management must not sacrifice infec-
tion risk for potential cost savings incurred by postoper-
ative hospital stays for postoperative IV antibiotics. Our
study suggests that postoperative IV antibiotics are not
necessary, as the infection rate is not inferior with out-
patient oral antibiotic regimens.
In addition, hospital admissions are prohibited from
outpatient surgery centers, which may dissuade some
surgeons from performing CWR. Our results suggest
that CWR tympanomastoidectomy for cholesteatoma
could be safely performed on an outpatient basis.
There are limitations to this study. This study com-
pared infection rates to historical controls from another
institution. The ideal study to compare post-operative
intravenous versus oral antibiotic regimens in CWR
tympanomastoidectomy would be a prospective random-
ized control trial. More importantly, the data presented
here demonstrate that even without a historic control
comparison, the postoperative infection rate is very low
when patients are managed on an outpatient basis. Sec-
ond, the findings presented here are based upon analysis
of outcomes at a single institution under two surgeons.
While our patient population varied in age and socioeco-
nomic status, it is possible that these results may not be
generalizable to all patients and all situations.
CONCLUSIONS
Here we show that the infection rate of CWR tym-
panomastoidectomy with mastoid obliteration is low
when performed on an outpatient basis. The infection
rate is not inferior to those cases managed with postop-
erative intravenous antibiotics in a historical cohort. A
larger prospective trial is warranted.
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